BIMEDA Inc. has acquired the marketing rights to Ceva Animal Health's portfolio of equine products in the U.S., comprised of Tildren tiludronate disodium, altrenogest, ConfidenceEQ and PentosanEQ. Bimeda also acquired the marketing rights for Tildren in Canada.
"This agreement is a key milestone in Bimeda's strategic expansion into the equine market. With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America," said Alan Kelly, director of commercial development for Bimeda North America.
Founded in Ireland in the late 1960s, Bimeda is an international developer, manufacturer and marketer of veterinary pharmaceuticals and animal health products. In addition to distributing Bimeda-brand products in 70-plus countries, Bimeda also manufactures private-label products for distributors, agents and international companies.
Ceva Animal Health LLC offers a growing line of products to meet the health needs of companion animals, poultry and swine. The company's North American headquarters are in Lenexa, Kan.